Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk is working on a new obesity drug that could ... Semaglutide, the GLP-1 drug that Novo sells under the brand ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Researchers at the University of Copenhagen have developed a new weight-loss drug that may surpass the effectiveness of ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with Denmark-based Ascendis Pharma (ASND) to leverage the latter’s advanced ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Scientists from the University of Copenhagen say they have developed a drug that decreases appetite while increasing calorie ...